324 Participants Needed

PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2

(Palisade-2 Trial)

Recruiting at 15 trial locations
CB
PP
Overseen ByPayal Patel, PharmD
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: VistaGen Therapeutics, Inc.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a nasal spray called PH94B to help adults with social anxiety disorder feel less anxious during public speaking. The spray is used shortly before speaking, and its effects are measured by asking participants about their anxiety levels. The goal is to see if the spray is safe and effective.

Who Is on the Research Team?

ML

Michael Liebowitz

Principal Investigator

Medical Research Network

Are You a Good Fit for This Trial?

Inclusion Criteria

SAD is currently diagnosed by checking for symptoms in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, and confirming those symptoms with the MINI.
The clinician rated the individual's LSAS total score as ≥70 at Screening.
The Hamilton Depression Score was less than eighteen at the screening visit.
See 3 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

3 to 35 days
1 visit (in-person)

Treatment

Participants self-administer the nasal spray and participate in a 5-minute public speaking challenge

1 day
2 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment, including repeat safety and psychiatric assessments

1 week
1 visit (in-person)

What Are the Treatments Tested in This Trial?

Interventions

  • PH94B Nasal Spray
  • Placebo Nasal Spray
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Group I: PlaceboExperimental Treatment1 Intervention
Placebo intranasal spray (100 microliters to each nostril) one time
Group II: PH94BExperimental Treatment1 Intervention
3.2 micrograms PH94B intranasal spray (100 microliters to each nostril) one time

Find a Clinic Near You

Who Is Running the Clinical Trial?

VistaGen Therapeutics, Inc.

Lead Sponsor

Trials
12
Recruited
1,900+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security